VIVITRA
Brand:
VIVITRA
Manufacturer:
ZYDUS
Manufacturer Details
ZYDUS
Compositions:
Transtuzumab 150mg injection,
|
Strength
|
Rate
|
Packing Style
|
|
150mg
|
20263.65
|
vial injection
|
List of Related Indications:
List Of Drugs:
- Transtuzumab- Immunomodulator
Indication Type Description:
Pharmacology/ Pharmacokinetics
Indication:
Immunomodulator
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Transtuzumab Biopharmaceuticals Genetech Inc.
HERCEPTIN Inj. GENETECH Lyophillized powder for solution 440mg in multidose vials
Indication- Breast cancer treatment
Adjuvant breast cancer treatemt-
Do not administer as an intravenous IV push or Bolus
Contra-Indications:
WARNING-
Cardiomyopathy- Transtumab can result in subclinical and clinical cardiac failure manifesting as cardiac failure CHF anadecreased left ventrucular ejection fraction
Evaluate le ft ventricular fuction in all patients prior to and during treatment with trantuzumab
Infusion reaction and pulmonary toxicity- Transtuzumab admin can result in serious infusion reaction and pulmonary toxicity. Fatal infusion reaction have been reported
Pharmacology/ Pharmacokinetics:
Pharmacology- Transtuzumab is a humanized immuglobullin GI kapps monoclonal antibody that electively binds with high affinity to the extracelular domain of the HER2 protein
Absorption and Distrubution- The pharmocokientics of transzumab were studied in women with metastic cancer. Short duration of IV infusion of transtuzumab 10 to 500mg once weekly demonstrated dose dependent pharmacokinetcis.
Mean halif life increase and clearance decreased with increasing dose level
